Dysregulated expressions of PTEN, NF-κB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia

被引:7
|
作者
Fu, Huan [1 ,2 ]
Jin, Chenghao [1 ,2 ,3 ]
Zhu, Qingxiu [1 ,2 ,3 ]
Liu, Tingting [1 ,2 ]
Ke, Bo [1 ,2 ]
Li, Anan [1 ,2 ]
Zhang, Tingting [1 ,2 ,3 ]
机构
[1] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Hematol, 92 Aiguo Rd, Nanchang 330006, Jiangxi, Peoples R China
[2] Key Biol Lab Blood Tumor Cell Jiangxi Prov, Nanchang 330006, Jiangxi, Peoples R China
[3] Nanchang Univ, Med Coll, Nanchang 330006, Jiangxi, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
B cell lymphoma; biomarkers; reactive follicular hyperplasia; differentiation; expression; BURKITTS-LYMPHOMA; ACTIVATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to investigate the value of PTEN, NF-kappa B, WWP2, p53 and c-Myc expressions in distinguishing B cell lymphomas from reactive follicular hyperplasia (RFH), and their abilities to discriminate different B cell lymphoma subtypes. Lymphoma tissue samples were obtained from 30 follicular lymphoma (FL) patients, 30 germinal center B-cell like (GCB) diffuse large B cell lymphoma (DLBCL) patients, 30 non-GCB DLBCL patients and 30 Burkitt's lymphoma (BL) patients. And hyperplasia tissue samples were obtained from and 30 RFH patients. Immunohistochemistry was used to quantify the expressions of PTEN, NF-kappa B, WWP2, P53 and c-Myc. PTEN expression was elevated in GCB DLBCL and BL compared with RFH, and in GCB DLBCL, non-GCB DLBCL and BL than that in FL; WWP2 expression was higher in FL GCB DLBCL, non-GCB DLBCL and BL compared with RFH; p53 expression increased in non-GCB DLBCL compared with RFH, and in BL compared with RFH, FL or GCB DLBCL; c-Myc expression was higher in GCB DLBCL, non-GCB DLBCL and BL compared with RFH; c-Myc expression was elevated in GCB DLBCL, non-GCB DLBCL and BL compared with FL. Additionally, PTEN negatively correlated with p53 expression in FL and CGB DLBCL, whereas NF-kappa B negatively correlated with WWP2 in GCB DLBCL, but positively associated with PTEN in RFH and c-Myc in BL. PTEN, WWP2, p53 and c-Myc expressions might be served as biomarkers for identification of B cell lymphomas from RFH as well as distinguishing different B cell lymphoma subtypes.
引用
收藏
页码:1092 / 1101
页数:10
相关论文
共 50 条
  • [1] Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, C-myc, Bcl-XL, NF-κB, and p53
    Han, SS
    Chung, ST
    Robertson, DA
    Ranjan, D
    Bondada, S
    CLINICAL IMMUNOLOGY, 1999, 93 (02) : 152 - 161
  • [2] Induction of TNF-sensitive cellular phenotype by c-myc involves p53 and impaired NF-κB activation
    Klefstrom, J
    Arighi, E
    Littlewood, T
    Jäättelä, M
    Saksela, E
    Evan, GI
    Alitalo, K
    EMBO JOURNAL, 1997, 16 (24): : 7382 - 7392
  • [3] Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma
    Madrigal-Velázquez, M
    Avilés, A
    Neri, N
    Huerta, J
    Martínez-Jaramillo, G
    Mayani, H
    LEUKEMIA & LYMPHOMA, 2006, 47 (04) : 665 - 673
  • [4] The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma
    Patrascu, Ana-Maria
    Rotaru, Ionela
    Olar, Lavinia
    Patrascu, Stefan
    Ghilusi, Mirela-Corina
    Neamtu, Simona-Daniela
    Nacea, Janina Georgiana
    Gluhovschi, Adrian
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (03): : 837 - 843
  • [5] Molecular features of primary mediastinal B-cell lymphoma:: involvement of p16INK4A, p53 and c-myc
    Scarpa, A
    Moore, PS
    Rigaud, G
    Inghirami, G
    Montresor, M
    Menegazzi, M
    Todeschini, G
    Menestrina, F
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) : 106 - 113
  • [6] B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene
    D Lens
    LJA Coignet
    V Brito-Babapulle
    CSP Lima
    E Matutes
    MJS Dyer
    D Catovsky
    Leukemia, 1999, 13 : 873 - 876
  • [7] B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene
    Lens, D
    Coignet, LJA
    Brito-Babapulle, V
    Lima, CSP
    Matutes, E
    Dyer, MJS
    Catovsky, D
    LEUKEMIA, 1999, 13 (06) : 873 - 876
  • [8] NF-κB-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status
    Sayyadi, Mohammad
    Safaroghli-Azar, Ava
    Safa, Majid
    Abolghasemi, Hassan
    Momeny, Majid
    Bashash, Davood
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (01): : 153 - 165
  • [9] Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL)
    Palestro, G
    Ponti, R
    Chiusa, L
    Chiarle, R
    Geuna, M
    Novero, D
    Freilone, R
    Pich, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1997, 59 (03) : 148 - 154
  • [10] Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-κB/rel complexes
    Yan-Hong Huang
    Jim Yujin Wu
    Yujin Zhang
    Mei X Wu
    Oncogene, 2002, 21 : 6819 - 6828